Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors

被引:96
|
作者
Sunderkoetter, C. [1 ]
Herrgott, I. [1 ]
Brueckner, C. [2 ]
Moinzadeh, P. [3 ]
Pfeiffer, C. [4 ]
Gerss, J. [5 ]
Hunzelmann, N. [3 ]
Boehm, M. [1 ]
Krieg, T. [3 ]
Mueller-Ladner, U. [6 ]
Genth, E. [7 ]
Schulze-Lohoff, E. [8 ]
Meurer, M. [4 ]
Melchers, I. [9 ]
Riemekasten, G. [2 ]
机构
[1] Univ Munster, Dept Dermatol, D-48149 Munster, Germany
[2] Charite Univ Med Berlin, Berlin, Germany
[3] Univ Cologne, Dept Dermatol & Venerol, Cologne, Germany
[4] Dresden Univ Hosp, Dept Dermatol, Dresden, Germany
[5] Univ Munster, Coordinating Ctr Clin Trials, Dept Med Informat & Biomath, D-48149 Munster, Germany
[6] Univ Giessen, Kerckhoff Clin, Dept Rheumatol & Clin Immunol, Bad Nauheim, Germany
[7] Univ Aachen, D-5100 Aachen, Germany
[8] Hosp Cologne Merheim, Med Clin 1, Cologne, Germany
[9] Univ Med Ctr Freiburg, Clin Res Unit Rheumatol, Freiburg, Germany
关键词
digital ulcers; German Network; Raynaud's phenomenon; risk factors; systemic sclerosis; RAYNAUDS-PHENOMENON; GERMAN NETWORK; SCLERODERMA TRIALS; ILOPROST TREATMENT; DISEASE; PATHOPHYSIOLOGY; CONSEQUENCES; DERMATOLOGY; MULTICENTER; MANAGEMENT;
D O I
10.1111/j.1365-2133.2008.09004.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Digital ulcers (DU) are a major complication in the course of systemic sclerosis (SSc). In recent years, efficacious, but expensive therapies (e. g. iloprost, sildenafil, bosentan) have been shown to improve healing or to reduce the recurrence of DU. For optimal management it would be useful to identify the risk factors for DU. Such statistical analyses have been rare because they require a high number of patients. Objectives To identify potential risk factors for DU in patients with SSc. Methods We used the registry of the German Network for Systemic Scleroderma and evaluated the data of 1881 patients included by August 2007. We assessed potential risk factors for DU by comparing patients with (24.1%) and without active DU at time of entry (75.9%). Results Multivariate analysis revealed that male sex, presence of pulmonary arterial hypertension (PAH), involvement of the oesophagus, diffuse skin sclerosis (only when PAH was present), anti-Scl70 antibodies, young age at onset of Raynaud's phenomenon (RP), and elevated erythrocyte sedimentation rate (ESR) significantly impacted on the appearance of DU. Certain combinations increased the patients' probability of presenting with DU, with the highest probability (88%) for male patients with early onset of RP, ESR > 30 mm h(-1), anti-Scl70 antibodies and PAH. Patients with DU developed RP, skin sclerosis and organ involvement approximately 2-3 years earlier than patients without DU. Conclusions The results reveal possible risk factors for the occurrence of DU in SSc. As DU are prone to local complications, prophylactic vasoactive treatment for patients presenting with these factors may be justified.
引用
收藏
页码:835 / 843
页数:9
相关论文
共 50 条
  • [21] Sildenafil in the treatment of ulcers digital in patients with systemic sclerosis
    Cairoli, E.
    Garra, V.
    Martinez, M.
    ACTAS DERMO-SIFILIOGRAFICAS, 2009, 100 (09): : 830 - 832
  • [22] Geographic variation as a risk factor for digital ulcers in systemic sclerosis patients: a multicentre registry
    Souza, E. J. R.
    Muller, C. S.
    Horimoto, A. M. C.
    Rezende, R. A.
    Guimaraes, I.
    Mariz, H. A.
    Dantas, A. T.
    Da Costa, I. P.
    Del-Rio, A. P. T.
    Sekiyama, J.
    Kahwage, C. B.
    Kayser, C.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2017, 46 (04) : 288 - 295
  • [23] Skin ulcers in systemic sclerosis: Possible role of inflammatory and angiogenetic factors
    Alivernini, S.
    Tolusso, B.
    De Santis, M.
    Bosello, S.
    Peluso, G.
    Pinnelli, M.
    Ferraccioli, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : A55 - A55
  • [24] Treatment of digital ulcers in systemic sclerosis
    Sevdalina Lambova
    Ulf Müller-Ladner
    Nature Reviews Rheumatology, 2011, 7 : 5 - 6
  • [25] Dynamics of digital ulcers in systemic sclerosis
    Bobeica, Carmen
    Laurentiu Tatu, Alin
    Craescu, Mihaela
    Solovastru, Laura
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (01) : 61 - 67
  • [26] Management of digital ulcers in systemic sclerosis
    Barsotti, Simone
    Di Battista, Marco
    Venturini, Valentina
    Della Rossa, Alessandra
    Mosca, Marta
    CHRONIC WOUND CARE MANAGEMENT AND RESEARCH, 2019, 6 : 9 - 18
  • [27] Health Care Utilization in Systemic Sclerosis Patients With Digital Ulcers
    Nevskaya, Tatiana
    Calderon, Leonardo M.
    Baron, Murray
    Pope, Janet E.
    ARTHRITIS CARE & RESEARCH, 2023, 75 (05) : 1071 - 1078
  • [28] THE PREVALENCE OF OSTEOMYELITIS IN INFECTED DIGITAL ULCERS IN SYSTEMIC SCLEROSIS PATIENTS
    Braun-Moscovici, Y.
    Keidar, Z.
    Braun, M.
    Markovits, D.
    Toledano, K.
    Tavor, Y.
    Sabbah, F.
    Rozin, A.
    Dolnikov, K.
    Balbir-Gurman, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 910 - 910
  • [29] Bosentan for treatment of active digital ulcers in patients with systemic sclerosis
    Launay, D
    Diot, É
    Pasquier, É
    Mouthon, L
    Boullanger, N
    Fain, O
    Jego, P
    Carpentier, P
    Hatron, PY
    Hachulla, É
    PRESSE MEDICALE, 2006, 35 (04): : 587 - 592
  • [30] BOSENTAN FOR DIGITAL ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS: SINGLECENTER EXPERIENCE
    Kucuksahin, O.
    Ates, A.
    Ilgrn, U.
    Ozturk, B.
    Kinikli, G.
    Turgay, M.
    Duzgun, N.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : S79 - S79